Completing the Cell Therapy Revolution
With no specific antigens available and a highly immunosuppressive microenvironment with little blood flow, how will researchers tackle solid tumors and bring cell therapy to millions?
With no specific antigens available and a highly immunosuppressive microenvironment with little blood flow, how will researchers tackle solid tumors and bring cell therapy to millions?
CatSci Ltd, a scientifically-led, commercially-minded and award-winning innovation partner for medicines development was proud to host Vaughan Gething MS, Welsh Minister of Economy, at its facility in Cardiff to open a new material science laboratory.
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebral Dopamine Neurotrophic Factor), today announced that results from the Nanoform Proof of Concept (PoC) project show that the nanoforming process has been successfully applied to Herantis’ rhCDNF drug candidate.
For many years, medical devices played second fiddle to medicines in the pharmaceutical industry. Their role was to facilitate the use of the “star” products, the drugs.